CRMD
Biotechnology · Healthcare
Equibles does not estimate personal net worth.
The proxy statement of CorMedix Inc. reports total compensation of $1,136,328 for Elizabeth Masson-Hurlburt in fiscal 2021, including a base salary of $310,800. Disclosed compensation is on record for 3 fiscal years. Elizabeth Masson-Hurlburt has spoken on 2 earnings calls across 1 company, most recently for CorMedix Inc. on May 14, 2026. The companies whose calls Elizabeth Masson-Hurlburt spoke on are classified in the Healthcare sector.
“As Joe mentioned, we were delighted to announce preliminary top line results of the ReSPECT study at the end of April.”
“The combined clinical development and operation teams, along with field medical affairs have been working diligently on numerous clinical activities.”
Proxy statement
Start not stated–2022-08-30
Last confirmed by a filing; no departure on record
CRMD
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | CorMedix Inc. (CRMD) | Executive Vice President and Head of Clinical Operations | $310,800 | $1,136,328 |
| 2020 | CorMedix Inc. (CRMD) | Executive Vice President and Head of Clinical Operations | $291,792 | $796,273 |
| 2019 | CorMedix Inc. (CRMD) | Executive Vice President and Head of Clinical Operations | $280,000 | $671,438 |